ストックスクリーナーアプリを入手
14.71
0.41%
-0.06
アフターアワーズ：
14.71
Replimune Group Inc (REPL) 最新ニュース
Replimune Group Lawsuit Focuses on FDA Disclosure Issues and Sharp REPL Stock Drop - TipRanks
Robbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Action - PR Newswire
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
DEADLINE ALERT for BZAI, BABA, ALAR, and REPL: The Law - GlobeNewswire
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - YCharts
Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today? - Stocktwits
Replimune (REPL) Results at a Glance: Profit Per Share Falls Below Its Benchmark; Market Response: Shares Move Lower 3.31% in the Available RecordFinancial Summary - vinanet.vn
REPL UPCOMING DEADLINE: SueWallSt Alerts Replimune Group, Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, - GlobeNewswire
Replimune (REPL) Earnings Update: The Bottom-Line Figure Trails Its Comparison in the Latest Reading; Market Reaction: The Stock Ends Down 3.88% in the Latest ReadingDownward Estimate Revision - vinanet.vn
Replimune CFO Emily Hill sells $132,175 in stock for tax obligations - Investing.com Canada
Replimune Group (NASDAQ:REPL) CFO Sells $132,175.68 in Stock - MarketBeat
Deadline Alert: Replimune Group, Inc. (REPL) Shareholders - GlobeNewswire
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Press Release: Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
Replimune faces securities lawsuit over alleged FDA disclosure omissions on RP1 drug approval risks. - Pluang
REPL STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Replimune Soars Over 120% as FDA Panel Backs Melanoma Therapy Ahead of August Decision - finance.biggo.com
Trump picks White House adviser Heidi Overton to run FDA, source says - marketscreener.com
NASDAQ: REPL Investor Alert: Lawsuit against Replimune Group, Inc. seeks to recover Investor losses - openPR.com
Replimune Group (NASDAQ:REPL) Shares Up 5.2%What's Next? - MarketBeat
Shareholders of Replimune Group urged to join c... - Pluang
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. LawsuitREPL - PR Newswire
REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug? - Stocktwits
REPL Ignites On Doctor Fury Against FDA’s Melanoma Drug Snub — Health Sec Steps Back - Stocktwits
Quantinno Capital Management LP Increases Stock Position in Replimune Group, Inc. $REPL - MarketBeat
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome - Stocktwits
Did You Lose Money Investing in Replimune Group, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About their Rights Against REPL - The Globe and Mail
REPL DEADLINE: Levi & Korsinsky Reminds Replimune Group, - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
2026-08-16 | REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:REPL | Press Release - Stockhouse
Replimune Raises $150 Million To Fund TUDRIQEV Launch And Confirmatory Trial - Pulse 2.0
REPL SWOT Analysis: FDA Approval of TUDRIQEV Marks a Turning Point - GuruFocus
Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line - Stocktwits
Replimune Group (NASDAQ:REPL) Releases Quarterly Earnings Results - MarketBeat
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Form 8K Replimune Group Inc For: 7 August By Investing.com - Investing.com Nigeria
Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed - TradingView
Replimune (NASDAQ: REPL) secures FDA accelerated approval and raises $141M - Stock Titan
Replimune Group (REPL): Ridgeback Capital now reports 3.5% ownership stake - Stock Titan
Why Is Replimune (NASDAQ:REPL) Drawing Attention After Its Oncology Approval? - Kalkine Media
Replimune Group Releases Q1 2027 Financial Results - AlphaStreet
2026-08-14 | REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:REPL | Press Release - Stockhouse
Replimune Group stock may move 5.6% on earnings release By Investing.com - Investing.com Canada
REPL Shareholder Alert: Replimune Group, Inc. Securities - GlobeNewswire
Replimune Group stock may move 5.6% on earnings release - Investing.com
Replimune Q1 EPS $(0.72) beats estimate; FDA approves TUDRIQEV - scanx.trade
Form 8K Replimune Group Inc For: 14 August By Investing.com - Investing.com Australia
Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update - TradingView
0.00%
3.22%
大文字化:
|
ボリューム (24 時間):